Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Claudia Calderaio
Observed name:
C. Calderaio
Institutions:
Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale",
Scuola Superiore Meridionale
Observed institutions:
Federico II University Hospital,
Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale",
Scuola Superiore Meridionale,
University of Naples Federico II
ORCID:
0009-0005-2804-3170
Observed ORCID:
0009-0005-2804-3170
OpenAlex ID:
A5092537602
CAR-T cell therapy for breast cancer: Current status and future perspective
2024
·
Giuseppe Buono
, Monica Capozzi
, et al.
·
Cancer Treatment Reviews
·
31
Central obesity, body mass index, metabolic syndrome and mortality in Mediterranean breast cancer patients
2023
·
Anna Crispo
, Livia S. A. Augustin
, et al.
·
Scientific Reports
·
26
PDF
Datopotamab deruxtecan: rational strategies, novel advancements, challenges, and future perspectives
2025
·
Vincenzo Di Lauro
, Alessandro Rizzo
, et al.
·
Cancer Treatment Reviews
·
16
The multidisciplinary management of HER2-positive breast cancer brain metastases: from new biological insights to future therapeutic options
2024
·
Claudia von Arx
, Claudia Calderaio
, et al.
·
Frontiers in Oncology
·
3
PDF
315P Real-world safety and effectiveness of T-DXd in older advanced breast cancer Patients: Updated analysis in an expanded cohort from the TREX-old registry
2025
·
A. Deleuze
, S. Nardin
, et al.
·
ESMO Open
·
2
PDF
The long road after breast cancer: survivorship issues and long-term treatment effects in young women
2026
·
Martina Pagliuca
, Roberto Buonaiuto
, et al.
·
Frontiers in Oncology
·
1
PDF
Prognostic value of hormone receptor expression in patients with HR+/HER2− advanced BC treated with first-line ET+CDK4/6i: results from the multicentre observational, real-world PALMARES-2 study
2026
·
Francesca Ligorio
, Leonardo Provenzano
, et al.
·
EClinicalMedicine
AI-Enhanced PROMs and Drug-Drug Interaction Screening in Advanced Breast Cancer: Protocol of a Prospective Observational Pilot Study
2026
·
Ornella Tinelli
, Claudia Von Arx
, et al.
·
Epidemiology Biostatistics and Public Health
PDF
CDK4/6i in the Underrepresented Histological Subtypes of HR±/HER2- Metastatic Breast Cancer: A Real-World Cohort Study of Effectiveness and Safety
2026
·
Claudia von Arx
, Alessandra Calabrese
, et al.
·
Clinical Breast Cancer
568eP Early progression to CDK4/6 inhibitors plus endocrine therapy in HR+/HER2− metastatic breast cancer: A real-world analysis
2026
·
M. Tafuro
, M. Piezzo
, et al.
·
ESMO Open
557eP OVAL-T-Dxd: Real-world assessment of ovarian function suppression (OFS) during trastuzumab deruxtecan (T-Dxd) therapy in premenopausal, hormone-receptor–positive (HR+/HER2-Low) metastatic breast cancer (mBC)
2026
·
S. Parola
, O. Tinelli
, et al.
·
ESMO Open
PDF
Abstract PS4-07-13: Safety and Efficacy of Immune Checkpoint Inhibitors in Early Triple Negative Breast Cancer: A Systematic Review and Meta-Analysis of Real-World Evidence vs. Clinical Trial Data
2026
·
A. Longobardi
, R. Buonaiuto
, et al.
·
Clinical Cancer Research
310P Immune-related adverse events in early triple-negative breast cancer: A meta-analysis of real-world evidence vs. clinical trial data
2025
·
A. Longobardi
, C. Calderaio
, et al.
·
Annals of Oncology
373P Association between CDK4/6 inhibitor (i) clinical outcomes and breast cancer (BC) histotypes
2025
·
C. von Arx
, A. Calabrese
, et al.
·
ESMO Open
PDF
286P Assessment of non-genetic factors with breast cancer risk in women BRCA carriers
2025
·
A. Calabrese
, M. Fordellone
, et al.
·
ESMO Open
Show more works
View as search
Works count:
15
Citation count:
79
H-index:
3
I10-index:
3
Year
Topic
Type